World ADC 2025 – San Diego: Highlights and Event Recap

The 16th World ADC San Diego 2025 conference was held in San Diego, California, from November 3 to November 6, 2025. As the world’s largest antibody-drug conjugate, the exhibition theme was: “Progressing ADCs to Standard of Care Oncology Treatments by Moving the Needle Through Innovation in ADC Chemistry, Improving Patient Stratification for Clinical Trials & Optimizing Manufacturing Efficiency”. 

Topics included:

• Bringing ADCs to Earlier Line Oncology Therapies: Showcasing ADC Development Providing Long-Term Benefit to Patients 

• Evaluating Performance of Novel ADC Design & MoA Differentiation to Assess Activity Versus Validated Clinical Successes 

• Spotlighting ADC Clinical & Approval Success Across 2024 & 2025 Driving ADC Access to Wider Patient Populations 

• Putting the “Why” Behind ADC Clinical Profiles & Learning from the Past to Lay the Groundwork for Next-Generation ADCs 

→ Biointron’s Highlighted Points:

1. Bringing ADCs to Earlier-Line Oncology Therapies

• Expanding ADCs into first- and second-line indications for breast, lung, and urothelial cancers. 

• Emphasis on combination regimens with checkpoint inhibitors and targeted therapies to improve durability. 

• Improved bystander effect control via optimized linker–payload balance for better tumor selectivity. 

• Clinical data confirm that HER2-low and TROP2 ADCs sustain long-term disease control in heavily pretreated patients. 

• Early use supported by predictive biomarkers to stratify responders and guide dosing strategy. 

• Focus on re-treatment and sequencing studies, showing extended benefit with novel conjugate architectures. 

2. Evaluating Performance of Novel ADC Design & MoA Differentiation

• Comparative studies of topoisomerase I, microtubule, and DNA-damaging payloads highlighted distinct MoA advantages. 

• Dual-payload and bispecific ADCs demonstrate synergy against resistant and heterogeneous tumor models. 

• Adoption of site-specific conjugation delivers more stable DAR control and reproducible PK. 

• Mechanistic modeling links internalization kinetics and trafficking pathways to potency optimization. 

• Tumor microenvironment-responsive linkers (pH, enzymatic) improve payload release precision. 

• New analytical assays quantify on-target vs. off-target cytotoxicity, guiding next-gen design refinement. 

3. Spotlighting ADC Clinical & Approval Success (2024–2025)

• Multiple global regulatory approvals across HER3, CEACAM5, and Nectin-4 targets mark ADC maturity. 

• Strong performance from enhanced topoisomerase-based ADCs underscores clinical reliability and safety improvements. 

• Growing geographic access through Japan, Korea, and EU filings expands patient availability. 

• Manufacturing scale-up and CMC standardization enabling faster transition from trial to launch. 

• Breakthrough status designations highlight durable responses and renewed confidence in ADC class versatility. 

4. Putting the “Why” Behind ADC Clinical Profiles

• Lessons from first-generation ADCs inform optimized dosing, safety margins, and patient selection. 

• Toxicity management refined via target expression mapping and linker stability tuning. 

• Fc engineering and payload hydrophilicity adjustments mitigate hematologic and ocular AEs. 

• Cross-study data identify DAR uniformity and conjugation site as predictors of clinical consistency. 

• Translational modeling links tumor antigen density and payload release rate to response outcomes. 

• Future outlook centers on AI-guided design and real-time PK monitoring, bridging lab to clinic. 

Thank you to everyone who visited our booth at World ADC 2025 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.